WARRANTS TO PURCHASE COMMON STOCK |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants To Purchase Common Stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
WARRANTS TO PURCHASE COMMON STOCK |
NOTE 14 – WARRANTS TO PURCHASE COMMON STOCK The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at June 30, 2025:
During the six months ended June 30, 2025, 13,666; 5,758 (as the Company received FDA acceptance of our NDA filing), and 1 warrants with an exercise price of $1,056, $1,776 and $364,800, respectively, expired. During the six months ended June 30, 2024, 33,841 prefunded common warrants were exercised. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure of stock warrants. No definition available.
|